Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on August 14, 2025
AppTech Payments Corp. Highlights Q2 2025 Financial and Strategic Developments
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech” or the “Company”) (NASDAQ: APCX), a fintech company innovating payment solutions for businesses, today announced financial results for the second quarter ended June 30, …
VERSES Announces Filing of Quarterly Report on Form 10-Q
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES" or the "Company"), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its …
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
Digi Power X Reports Solid Mid-Year Financial Position, Removal of ‘Going Concern’ Risk and Positive Adjusted EBITDA in Q2 2025
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …
YXT.com to Announce Financial Results for the First Six Months of 2025 on August 20, 2025
SUZHOU, China, Aug. 14, 2025 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions in China, today announced that it plans to report its financial results …
INVO Fertility Announces Second Quarter 2025 Financial Results
SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and …
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “ …
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis …
BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025
MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market …
CELOXFI Implements Military-Grade Security Protocols, Achieves 100% User Asset Insurance Coverage
GOLDEN, CO , Aug. 14, 2025 (GLOBE NEWSWIRE) -- Celoxfi, the AI-powered crypto asset exchange, today announced a landmark upgrade to its security infrastructure, setting a new industry benchmark for user protection. The platform has secured 100% insurance …
Veea Inc. Announces Closing of $9.2 Million Public Offering
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Veea Inc. (NASDAQ: VEEA) (“Veea” or the “Company”), a leader in intelligent edge infrastructure, announced the closing of its public offering of an aggregate of 9,189,096 shares of common stock and warrants to …
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, …
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season …
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction in symptomatic COVID-19, resembling …
MDB Capital Holdings to Host Second Quarter 2025 Update Conference Call on Wednesday August 27, 2025, at 4:30 p.m. Eastern Time
Addison, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Wednesday August 27, 2025 at …
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® ( …
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind …
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney …
Chris Barranco Joins Quick Custom Intelligence as Director of Business Development
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI), a leading provider of AI-driven analytics and enterprise solutions for the gaming and hospitality industry, today announced the addition of Chris Barranco as Director of Business …